STOCK TITAN

Electromed Stock Price, News & Analysis

ELMD NYSE

Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.

Electromed Inc. (ELMD) specializes in advanced airway clearance solutions through its clinically validated SmartVest system. This dedicated news hub provides investors and healthcare stakeholders with essential updates on respiratory care innovations, regulatory compliance, and corporate developments.

Find authoritative coverage of ELMD's progress in HFCWO technology, including product enhancements, partnership announcements, and quality certifications. Our curated news selection emphasizes factual reporting on clinical trial outcomes and market expansion initiatives within the medical device sector.

Regular updates include earnings disclosures, manufacturing quality milestones, and research collaborations. Bookmark this resource for streamlined access to verified ELMD developments that impact respiratory therapy standards and investment considerations.

Rhea-AI Summary

Electromed (NYSE American: ELMD), a leader in airway clearance technologies, has announced it will release its fiscal 2025 first quarter financial results on November 12, 2024, after market close. Management will host a conference call at 5:00 p.m. Eastern Time to discuss the results. Investors can join via phone at (844) 826-3033 (Domestic) or (412) 317-5185 (International), or watch the webcast through the company's Investor Relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.06%
Tags
conferences earnings
-
Rhea-AI Summary

Electromed (NYSE American: ELMD) has appointed Peter Horwich as Vice President, Marketing. Horwich brings over 20 years of experience in Medical Technology marketing, previously serving at Abiomed (now J&J MedTech) where he directed Global Strategic Marketing for Respiratory Therapies. His experience includes roles at Medtronic, Arizant, Entegris, and Guidant. CEO Jim Cunniff highlighted that this strategic appointment comes during a period of business growth and aims to drive therapy adoption for SmartVest Clearway to support revenue growth goals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
management
-
Rhea-AI Summary

Electromed (NYSE American: ELMD), a leader in airway clearance technologies, has announced a new $5.0 million share repurchase authorization effective September 11, 2024. This follows the completion of their previous repurchase program in Q4 fiscal 2024. The company's board will determine the timing and amount of repurchases based on market conditions. Repurchases may be made through various means, including open market transactions and block trades.

CEO Jim Cunniff stated that this decision follows Electromed's record performance in fiscal 2024 and reflects the board's confidence in future growth. The company's strong revenue growth and profitability are generating robust free cash flow, allowing for shareholder value creation while continuing business investments. Management believes the stock is undervalued given their strong financial results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
buybacks
Rhea-AI Summary

Electromed, Inc. (NYSE American: ELMD) reported record financial results for Q4 and FY 2024. Highlights include:

- Q4 net revenues increased 9.0% to $14.8 million
- Q4 operating income up 56.3% to $2.3 million
- Q4 net income reached $1.8 million or $0.20 per diluted share
- FY 2024 net revenue grew 13.8% to $54.7 million
- FY 2024 operating income increased 64.2% to $6.6 million
- FY 2024 net income totaled $5.2 million or $0.58 per diluted share

The company attributed growth to investments in commercial infrastructure and market development initiatives. As of June 30, 2024, Electromed had $16.1 million in cash, $23.3 million in accounts receivable, and no debt.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.54%
Tags
-
Rhea-AI Summary

Electromed, Inc. (NYSE American: ELMD), a leader in innovative airway clearance technologies, has announced its upcoming financial results release and conference call for the fourth quarter of fiscal 2024. The company will issue its financial results press release on August 27, 2024, after the stock market closes. Management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.

Interested parties can participate in the call by dialing (877) 407-0789 (Domestic) or (201) 689-8562 (International). A live webcast will be accessible on Electromed's website in the Investor Relations section. For those unable to listen live, a replay will be available by phone and online.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
conferences earnings
-
Rhea-AI Summary

Electromed, a leader in innovative airway clearance technologies, announced its participation in the Canaccord Genuity 44th Annual Global Growth Conference in Boston from August 13-15, 2024. Jim Cunniff, President and CEO, and Brad Nagel, CFO, will present on Wednesday, August 14, 2024, at 2:30 p.m. Eastern Time.

The presentation will be available via live and archived webcast on Electromed's website under Events & Presentations. Additionally, Electromed has published an updated investor presentation deck for review, accessible on their website and the SEC website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

Electromed, known for its innovative airway clearance technologies, announced that its top executives, President and CEO Jim Cunniff and CFO Brad Nagel, will attend the 2024 Sidoti June Small-Cap Virtual Conference. This event is scheduled for June 12-13, 2024. Electromed will present at 1:45 p.m. ET on June 12, 2024. A live and archived webcast of their presentation will be accessible via the Electromed website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
conferences
-
Rhea-AI Summary

Electromed, Inc. achieves record revenue in the third quarter of fiscal year 2024, with a 15% increase to $13.9 million compared to the prior year. Operating income rises by 54%, net income reaches $1.49 million, and cash balance grows to $11.7 million. The company's direct homecare business revenue increases by 12%, showing strong growth and operational efficiency. The gross profit margin remains stable at 75%. Electromed continues to focus on driving adoption of its products, enhancing shareholder value, and sustaining operating leverage for profitability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
conferences

FAQ

What is the current stock price of Electromed (ELMD)?

The current stock price of Electromed (ELMD) is $20.32 as of July 2, 2025.

What is the market cap of Electromed (ELMD)?

The market cap of Electromed (ELMD) is approximately 183.7M.
Electromed

NYSE:ELMD

ELMD Rankings

ELMD Stock Data

183.74M
6.65M
20.54%
43.56%
2.44%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
NEW PRAGUE